vs
Side-by-side financial comparison of Bitcoin Depot Inc. (BTM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $162.5M, roughly 1.2× Bitcoin Depot Inc.). On growth, Bitcoin Depot Inc. posted the faster year-over-year revenue change (20.1% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $2.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -4.9%).
Bitcoin Depot Inc. is one of the largest cryptocurrency ATM operators across North America. It provides retail consumers with accessible in-person kiosks to buy and sell Bitcoin and other leading digital assets, alongside online crypto purchase services via bank transfer. Its self-service kiosks are located in high-traffic retail spaces including grocery stores, gas stations and convenience stores.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BTM vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $162.5M | $196.9M |
| Net Profit | $5.5M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 7.3% | 1.2% |
| Net Margin | 3.4% | — |
| Revenue YoY | 20.1% | 5.1% |
| Net Profit YoY | 690.4% | — |
| EPS (diluted) | $0.08 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $196.9M | ||
| Q3 25 | $162.5M | $179.5M | ||
| Q2 25 | $172.1M | $181.1M | ||
| Q1 25 | $164.2M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $135.3M | $168.6M | ||
| Q2 24 | $163.1M | $178.0M | ||
| Q1 24 | $138.5M | $167.1M |
| Q4 25 | — | — | ||
| Q3 25 | $5.5M | $5.4M | ||
| Q2 25 | $6.1M | $-4.8M | ||
| Q1 25 | $4.2M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-939.0K | $-143.5M | ||
| Q2 24 | $-2.6M | $18.9M | ||
| Q1 24 | $-1.5M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | 7.3% | 3.5% | ||
| Q2 25 | 9.2% | 4.7% | ||
| Q1 25 | 10.8% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 4.1% | -82.8% | ||
| Q2 24 | 4.7% | 15.9% | ||
| Q1 24 | 0.5% | 7.9% |
| Q4 25 | — | — | ||
| Q3 25 | 3.4% | 3.0% | ||
| Q2 25 | 3.5% | -2.7% | ||
| Q1 25 | 2.6% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.7% | -85.1% | ||
| Q2 24 | -1.6% | 10.6% | ||
| Q1 24 | -1.1% | 5.4% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.08 | $0.12 | ||
| Q2 25 | $0.16 | $-0.11 | ||
| Q1 25 | $0.20 | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $-0.05 | $-3.11 | ||
| Q2 24 | $-0.13 | $0.39 | ||
| Q1 24 | $-0.25 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $59.3M | $238.4M |
| Total DebtLower is stronger | $67.5M | $372.2M |
| Stockholders' EquityBook value | $21.0M | $693.1M |
| Total Assets | $125.3M | $1.3B |
| Debt / EquityLower = less leverage | 3.21× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $238.4M | ||
| Q3 25 | $59.3M | $246.3M | ||
| Q2 25 | $48.0M | $445.9M | ||
| Q1 25 | $35.0M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $32.2M | $453.8M | ||
| Q2 24 | $43.9M | $404.2M | ||
| Q1 24 | $42.2M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | $67.5M | $376.7M | ||
| Q2 25 | $66.5M | $580.5M | ||
| Q1 25 | $56.2M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | $44.5M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $37.6M | — |
| Q4 25 | — | $693.1M | ||
| Q3 25 | $21.0M | $727.2M | ||
| Q2 25 | $4.7M | $757.8M | ||
| Q1 25 | $-4.6M | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $-7.9M | $749.6M | ||
| Q2 24 | $4.4M | $879.3M | ||
| Q1 24 | $5.0M | $892.2M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | $125.3M | $1.3B | ||
| Q2 25 | $109.1M | $1.5B | ||
| Q1 25 | $89.7M | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $87.4M | $1.5B | ||
| Q2 24 | $97.5M | $1.6B | ||
| Q1 24 | $90.1M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | 3.21× | 0.52× | ||
| Q2 25 | 14.18× | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | 9.27× | — | ||
| Q1 24 | 7.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $43.7M |
| Free Cash FlowOCF − Capex | $2.5M | $43.5M |
| FCF MarginFCF / Revenue | 1.6% | 22.1% |
| Capex IntensityCapex / Revenue | 2.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.1M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $43.7M | ||
| Q3 25 | $6.6M | $60.8M | ||
| Q2 25 | $10.2M | $12.0M | ||
| Q1 25 | $16.3M | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | $5.8M | $53.9M | ||
| Q2 24 | $10.1M | $53.2M | ||
| Q1 24 | $1.3M | $49.1M |
| Q4 25 | — | $43.5M | ||
| Q3 25 | $2.5M | $57.0M | ||
| Q2 25 | $9.8M | $9.3M | ||
| Q1 25 | $15.9M | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $-1.0M | $49.8M | ||
| Q2 24 | $7.6M | $51.6M | ||
| Q1 24 | $789.0K | $46.3M |
| Q4 25 | — | 22.1% | ||
| Q3 25 | 1.6% | 31.7% | ||
| Q2 25 | 5.7% | 5.1% | ||
| Q1 25 | 9.7% | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | -0.8% | 29.6% | ||
| Q2 24 | 4.7% | 29.0% | ||
| Q1 24 | 0.6% | 27.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 2.5% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.2% | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 5.0% | 2.4% | ||
| Q2 24 | 1.5% | 0.9% | ||
| Q1 24 | 0.4% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | 1.20× | 11.20× | ||
| Q2 25 | 1.67× | — | ||
| Q1 25 | 3.88× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTM
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
